October 8th 2024
The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been dosed.
September 25th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
March 23rd 2020In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Read More
Evolving Treatment Strategies in RET+ Lung Cancer Leave Unanswered Questions
March 23rd 2020Oncologists have unanswered questions about how to deal with resistance mechanisms for multikinase inhibitors and selective RET inhibitors, and how efficacy is impacted when they combine 2 or more such drugs into a treatment regimen for RET-positive lung cancer. In a paper, researchers led by Vivek Subbiah, et al review the existing data.
Read More
ASCO Issues Update on Frontline NSCLC Treatment in Wake of Immunotherapy Approvals
March 21st 2020In response to frequent and substantial changes in the treatment of non–small cell lung cancer in the frontline set­ting, the American Society of Clinical Oncology has partially updated its 2017 guide­line for the treatment of patients with stage IV disease without driver mutations.
Read More
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
March 21st 2020Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Read More
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20th 2020Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
Read More
Tremelimumab Added to Durvalumab and SoC Fails to Improve OS in ES-SCLC
March 17th 2020The addition of tremelimumab to frontline durvalumab and the standard of care, platinum-based chemotherapy, did not demonstrate a statistically significant improvement in overall survival in patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase III CASPIAN trial, according to high-level results from the final analysis of the trial.
Read More
Healthy People 2020 Initiative Demonstrates Progress on the Status of Cancer in the US
March 17th 2020To help assess the advances the United States has made in decreasing cancer-related deaths, a collective of public health bodies found that monitoring trends in cancer risk, screening test use, and mortality is informative. A report published in <em>Cancer</em> shows that progress has been made in recent years, but there is more work to be <a>done.</a>
Read More
Death By Cancer Shows Decline in the 2020 Annual Report to the Nation on the Status of Cancer
March 17th 2020From 2001 to 2017, the cancer death rates continued to decline in the United States, and these decreases were observed in all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016, according to the Annual Report to the Nation on the Status of Cancer, which was published in Cancer.<sup> </sup>
Read More
Vemurafenib Active as Monotherapy in BRAF V600 NSCLC
March 16th 2020Vemurafenib monotherapy is an effective treatment for patients with BRAF V600-mutated non–small cell lung cancer, according to results from the phase II AcSe vemurafenib trial II study published in the Annals of Oncology.
Read More
Anlotinib Extends Time to Brain Progression in Patients with Advanced NSCLC
March 14th 2020A post hoc analysis of the ALTER 0303 trial has found that anlotinib, compared with placebo, extended the time patients with advanced non-small cell lung cancer had before brain metastases developed or existing brain lesions increased in size, reports a recent paper in The Oncologist.
Read More
Alectinib Represents Promising Frontline Option for ALK-Positive NSCLC
March 13th 2020In an interview with Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, discussed the final progression-free survival data for frontline alectinib comparted with crizotinib as treatment of patients with advanced ALK-positive non–small cell lung cancer in the ALEX trial.
Read More
Pemetrexed-Based Chemotherapy Regimens Appear More Effective in RET-Positive NSCLC
March 12th 2020Pemetrexed-based chemotherapy regimens were more effective as treatment of patients with <em>RET</em>-rearranged non–<a>small</a> cell lung cancer compared with other regimens, according to a multicenter, retrospective study. This treatment also showed similar benefit for various <em>RET</em> fusion types, including <em>KIF5B-<a>RET </a></em>and non-<em>KIF5B-RET</em> fusions.
Read More
Bevacizumab Biosimilar Under Review by FDA
March 9th 2020The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.
Read More
A Look Back at FDA News from February 2020
March 4th 2020In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.
Read More